As I mentioned, I work at the pharmacoeconomics research unit. My job is to create cost-effectiveness analysis of new cancer drugs or to critique cost-effectiveness analysis of cancer drugs. I then explain it to a recommendation committee and say, for example, “We're getting two more months of life with this new cancer drug. It's going to cost an extra $30,000. Let me give you more context: there's no other treatment for this type of disease and this is seen as a big breakthrough.”
I do this regularly, helping people understand the information, helping them evaluate the information, and helping them use it.
Does that answer your question?